NCT05667402View on ClinicalTrials.gov

Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Central Nervous System LeukemiaAllogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

TBF regimen

The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.

DRUG

modified BuCY2 regimen

The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.

Trial Locations (1)

710061

First Affiliated Hospital of Xi'an Jiaotong University, Xi'an

All Listed Sponsors
lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER

NCT05667402 - Clinical Study of TBF Regimen in Allo-HSCT in Patients With CNS Leukemia | Biotech Hunter | Biotech Hunter